HCM (HUTCHMED (China)) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HCM HUTCHMED (China) Ltd HCM
78 GF Score
Price $14.09
GF Value $13.47
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is HUTCHMED (China) Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

HCM
78GF Score
HUTCHMED (China) Ltd HCM
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HUTCHMED (China) (HCM) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be overvalued. The current stock price of $14.09 is trading 4.6% above its estimated GF Value™ of $13.47. GuruFocus considers HUTCHMED (China) to be Fairly Valued.

Key valuation signals for HCM:

  • Future Policy Benefits:
  • GF Value™: $13.47 vs. price of $14.09 (4.6% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the HCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
78GF Score

Get the complete analysis for HCM

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price
$13.47
GF Value